

## The asthma-rhinitis multimorbidity is associated with IgE polysensitization in adolescents and adults

Valérie Siroux, Natalia Ballardini, Marion Soler, Christian Lupinek, Anne Boudier, Isabelle Pin, Jocelyne Just, Rachel Nadif, Josep Antó, Erik Melen, et al.

► **To cite this version:**

Valérie Siroux, Natalia Ballardini, Marion Soler, Christian Lupinek, Anne Boudier, et al.. The asthma-rhinitis multimorbidity is associated with IgE polysensitization in adolescents and adults. *Allergy*, Wiley, 2018, Epub ahead of print. 10.1111/all.13410 . inserm-01801965

**HAL Id: inserm-01801965**

**<https://www.hal.inserm.fr/inserm-01801965>**

Submitted on 28 May 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **The asthma-rhinitis multimorbidity is associated with IgE**

2 **polysensitization in adolescents and adults**

3

4 Valérie Siroux<sup>1</sup>, Natalia Ballardini<sup>2,3,4</sup>, Marion Soler<sup>1</sup>, Christian Lupinek<sup>5</sup>, Anne Boudier<sup>1</sup>,

5 Isabelle Pin<sup>1,6</sup>, Jocelyne Just<sup>7,8</sup>, Rachel Nadif<sup>9,10</sup>, Josep M Anto<sup>11</sup>, Erik Melen<sup>2,3</sup>, Rudolf

6 Valenta<sup>5</sup>, Magnus Wickman<sup>2,3,12</sup>, Jean Bousquet<sup>9,10</sup>

7

8 <sup>1</sup> University Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France

9 <sup>2</sup> Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

10 <sup>3</sup> Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden

11 <sup>4</sup> St John's Institute of Dermatology, King's College London, London, UK

12 <sup>5</sup> Division of Immunopathology, Department of Pathophysiology and Allergy Research,

13 Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna,

14 Austria

15 <sup>6</sup> CHU Grenoble Alpes, Department of Pediatrics, Grenoble, France

16 <sup>7</sup> Allergology department, Children Hospital Armand Trousseau, Paris, France

17 <sup>8</sup> Inserm, UMR-S 1136 INSERM and UPMC Paris, France

18 <sup>9</sup> Inserm, U1168, VIMA: Aging and chronic diseases. Epidemiological and public health

19 approaches, F-94807, Villejuif, France

20 <sup>10</sup> Univ Versailles St-Quentin-en-Yvelines, UMR-S 1168, F-78180, Montigny le Bretonneux,  
21 France

22 <sup>11</sup> ISGLoBAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain

23 <sup>12</sup> Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna Sweden

24

25 **Short Title**

26 Asthma-rhinitis multimorbidity and IgE polysensitization

27

28 **Corresponding author**

29 Valérie Siroux

30 Institut pour l'Avancée des Biosciences

31 Centre de Recherche UGA / Inserm U 1209 / CNRS UMR 5309

32 Equipe d'épidémiologie environnementale

33 Site Santé - Allée des Alpes

34 38700 La Tronche

35 [Valerie.siroux@univ-grenoble-alpes.fr](mailto:Valerie.siroux@univ-grenoble-alpes.fr)

36 Tel : +33 4 76 54 95 56

37

38 **Manuscript word count:** 3780

39 **Abstract word count:** 249

## 40 **Abstract**

41 **Background:** Children with multimorbid asthma and rhinitis show IgE polysensitization to  
42 several allergen sources. This association remain poorly studied in adolescents and adults  
43 using defined allergen molecules. We investigated IgE sensitization patterns towards a broad  
44 panel of aeroallergen components in adults and adolescents with a focus on individuals with  
45 asthma and rhinitis multimorbidity.

46 **Methods:** IgE reactivity to 64 microarrayed aeroallergen molecules was determined with the  
47 MeDALL-chip in samples from the French EGEA study (n=840, age=40.7±17.1) and the Swedish  
48 population-based birth cohort BAMSE (n=786, age=16±0.26). The age- and sex-adjusted  
49 associations between the number of IgE-reactive allergen molecules ( $\geq 0.3$  ISU) and the  
50 asthma-rhinitis phenotypes were assessed using a negative binomial model.

51 **Results:** Groups representing four phenotypes were identified: no asthma-no rhinitis (A-R-;  
52 30% in EGEA and 54% in BAMSE), asthma alone (A+R-; 11% and 8%), rhinitis alone (A-R+; 15%  
53 and 24%), and asthma-rhinitis (A+R+; 44% and 14%). The numbers of IgE-reactive aeroallergen  
54 molecules significantly differed between phenotypes (median in A-R-, A+R-, A-R+ and A+R+:  
55 0, 1, 2 and 7 in EGEA and 0, 0, 3, and 5 in BAMSE). As compared to A-R- subjects, the adjusted  
56 ratio of the mean number of IgE-reactive molecules was higher in A+R+ than in A+R- or A-R+  
57 (10.0, 5.4 and 5.0 in EGEA and 7.2, 0.7 and 4.8 in BAMSE).

58 **Conclusion:** The A+R+ phenotype combined the sensitization pattern of both the A-R+ and  
59 A+R-phenotypes. This multimorbid polysensitized phenotype seems to be generalizable to  
60 various ages and allergenic environments and may be associated with specific mechanisms.

61

62

63 **Key words**

64 Allergens, Epidemiology, Multimorbidity, Polysensitization, Specific-IgE

65

66 **Abbreviations**

67 A: Asthma

68 EGEA: Epidemiological study of the Genetics and Environment of Asthma, bronchial

69 hyperresponsivness and atopy

70 FP7: Framework Programme 7 (European Union)

71 IgE: Immunoglobulin E

72 ISAC: Immuno solid-phase allergen chip

73 ISU: Standardized units for specific IgE

74 MeDALL: Mechanisms of the development of allergy

75 R: Rhinitis

## 76 **Introduction**

77 Allergic diseases are complex and represent multiple phenotypes (1) such as clinically silent  
78 IgE sensitization, isolated phenotypes such as only rhinitis, asthma, dermatitis, food allergy,  
79 and multimorbidities associating several conditions in the same subject.

80 In children, multimorbidities of allergic diseases share common causal mechanisms that are  
81 partly IgE-mediated.(2) IgE sensitization is heterogeneous and important clinical and  
82 immunological differences exist between mono- and poly- sensitized patients.(3-5) An  
83 important result from the FP7-funded project MeDALL (Mechanisms of the Development of  
84 Allergy) was the identification of the multimorbid polysensitized phenotype of allergic  
85 diseases in children, characterized by children with asthma presenting both allergic  
86 polysensitization and other allergic diseases, mainly rhinitis.(5) Although polysensitization and  
87 allergic-related multimorbidity were known, they had not been associated in a single  
88 phenotype. In MeDALL, using hypothesis and data-driven methods, this novel phenotype was  
89 shown to be associated with some important features of allergic diseases including a low  
90 probability of remission of IgE sensitization and symptoms,(6-8) elevated levels of total and  
91 specific IgE,(9) high levels of blood eosinophils, and a high rate of allergy in family history. This  
92 newly described phenotype is also associated with the severity of asthma,(10-13) rhinitis,(11-  
93 13) atopic dermatitis(14) or food allergy.(15) However, this phenotype needs to be confirmed  
94 also in adolescents and adults, to understand whether these associations are transient or  
95 persistent along the life course. In a previous analysis in adults from the Epidemiological study  
96 of the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy - EGEA  
97 study, first evidence was provided that polysensitization is associated with multimorbid  
98 asthma and rhinitis.(16) However, the analysis was limited by use of allergen extracts which

99 represent mixtures of source-specific genuine allergen molecules and cross-reactive allergens  
100 so that a true discrimination of co- and cross-sensitization could not be made (17, 18) and by  
101 the fact that only a limited number of allergen extracts could be tested by skin prick testing.  
102 Until recently, the IgE sensitization profiling in allergic multimorbidity has been based on a  
103 limited number of allergens. Currently, the allergen micro-array technology makes it possible  
104 to measure allergen-specific IgE antibody responses to a large number of allergen molecules.  
105 In MeDALL, the immunoCAP ISAC chip technology (19, 20) was refined to increase its  
106 sensitivity and to incorporate new allergens.(20) The resulting MeDALL chip has been  
107 validated and tested in birth cohorts and allows measuring IgE responses to more than 170  
108 allergen components with a sensitivity similar to that of the traditional ImmunoCAP as  
109 validated using the major birch pollen allergen Bet v 1-specific IgE.(21-23)  
110 The present cross-sectional study investigates if the multimorbid polysensitized phenotype  
111 suspected in children could be generalized to adults and adolescents living in two different  
112 allergenic environments (France and Sweden) using different cohort designs (i.e., a cohort  
113 following a case-control study: EGEA, France (24) and a birth cohort: BAMSE, Sweden (25)).  
114 IgE sensitization patterns towards a large variety of respiratory allergen components were  
115 measured using the MeDALL micro-array technology.(21, 23)

116

## 117 **Methods**

### 118 ***Populations and study setting***

119 The present analysis relies on two populations, the EGEA study and the BAMSE birth cohort.

120 The EGEA1 study is composed of a group of 388 individuals with asthma enrolled in chest

121 clinics, 1,244 first-degree relatives and 415 control individuals.(26 )Participants were recruited  
122 through self-completed questionnaires and had a complete examination including pulmonary  
123 function tests.(24) About 11 years later, 1,601 participants (77.1% of the original cohort + 58  
124 new family members) took part in a complete examination (EGEA2). The analysis of IgE was  
125 conducted with serum samples from 840 adults at EGEA2 (463 with and 377 without asthma).  
126 Written consent was obtained from all participants. Ethical approval was obtained from the  
127 ethics committees (Necker-Enfants Malades Hospital, Paris for EGEA2).

128 BAMSE is a population-based birth cohort comprising 4,089 children from representative  
129 areas of Stockholm.(25) For this study, questionnaire data from baseline (2 months), 1, 2, 4,  
130 8, 12 and 16 years were used. Blood was drawn at 4, 8 and 16 years. Sera were available for  
131 64%, 60%, and 62% of the population.(6, 7) In 1,699 children, 42% of the original cohort, blood  
132 samples were available from all three clinical follow-ups (4, 8 and 16 years). Of these children,  
133 a subset of 800 was randomly selected. Permission for the study was obtained from the  
134 Regional Ethical Review board at Karolinska Institutet at each follow up and parents of  
135 participating children gave their informed consent.

136

### 137 ***Definition of asthma, allergic rhinitis and atopic dermatitis***

138 Validated questionnaires were used in both studies. In EGEA, ever asthma was defined by a  
139 positive answer to either *“Have you ever had attacks of breathlessness at rest with*  
140 *wheezing?”* or *“Have you ever had asthma attacks?”* or being recruited as an asthma case.  
141 Allergic rhinitis ever was defined by a positive answer to *“Have you ever had allergic rhinitis?”*  
142 or *“Have you ever had hay fever?”*. The age of asthma onset was estimated by  
143 questionnaire.(27) Age of rhinitis onset could not be evaluated since the questionnaire did not

144 include this information. Atopic dermatitis was defined by a positive response to “Have you  
145 ever had atopic dermatitis?”.

146 In BAMSE asthma at age 1 and 2 years was defined as at least three episodes of wheeze in  
147 combination with inhaled corticosteroids and/or signs of bronchial hyperreactivity without  
148 concurrent upper respiratory infection the past year before follow-up.(9) Asthma at 4, 8, 12  
149 and 16 years was defined as more than 3 episodes of wheeze in the last 12 months prior to  
150 the date of questionnaire and/or at least 1 episode of wheeze in the last 12 months in  
151 combination with inhaled steroids occasionally or regularly. Allergic rhinitis was defined as  
152 symptoms of sneezing, a runny or blocked nose, or itchy, red and watery eyes after exposure  
153 to furred pets or pollen in the past 12 months and/or doctor's diagnosis of allergic rhinitis  
154 since last follow up. Participants that fulfilled rhinitis definition or asthma definition at least  
155 one during the follow-ups at 1, 2, 4, 8, 12 or 16 years were classified as rhinitis ever and asthma  
156 ever. Atopic dermatitis was defined as dry skin, itchy rashes with age-specific location for 2  
157 weeks or more in the past 12 months and/or doctor’s diagnosis of atopic dermatitis.

158 Participants from EGEA and BAMSE were grouped in four phenotypes: no asthma & no rhinitis  
159 (A-R-), asthma alone (A+R-), rhinitis alone (A-R+), and asthma & rhinitis (A+R+). Multimorbidity  
160 was defined as having both asthma and rhinitis. For an exploratory analysis, we further  
161 considered atopic dermatitis.

162

### 163 ***Allergen-specific IgE measurement***

164 IgE reactivity to microarrayed allergens was determined in anonymized samples with the  
165 MeDALL-chip (multiplex microarray) in EGEA2 samples and in the 16-years old samples in  
166 BAMSE.(21, 23, 28, 29) The MeDALL-chip comprises 176 allergen components including aero-

167 and food allergen components. In the present study IgE responses to 64 defined clinically  
168 relevant respiratory allergenic molecules were studied (Table S1 in the *Supplements*). The  
169 measurement of allergen-specific IgE was performed as described.(6, 21) Results are given in  
170 ISU. According to previous studies, the positivity of each allergen-specific IgE was defined with  
171 a threshold of 0.3 ISU IgE.(6, 21, 22). As previously shown, the agreement between SPT and  
172 allergen-specific IgE in EGEA was strong (Cohen Kappa coefficient  $\geq 0.65$ ), with slightly higher  
173 prevalences using the MeDALL-chip (except for ragweed) (Table S2 in the *Supplements*).<sup>(28)</sup>  
174 In BAMSE, agreement for allergen-specific IgE between Immunocap and the MeDALL-chip  
175 components was high (Cohen Kappa coefficient  $\geq 0.75$ ) for the most prevalent allergens  
176 (thimothy grass, birch and cat) and moderate for the less prevalent allergens (house dust mite,  
177 horse and mugwort), as expected given the link between the kappa and the prevalence (Table  
178 S3 in the *Supplements*).

179 Within each study, respiratory allergenic molecules recognized by  $\geq 3\%$  of subjects were  
180 considered to address the sensitization profiles of asthma and rhinitis phenotypes (Table S1).

181

## 182 ***Biases***

183 In both studies, allergen-specific IgE was measured in a subset of samples (for cost issues),  
184 randomly selected among the BAMSE samples and in EGEA among the non-asthma and  
185 asthma samples separately. Within each group, the selection process was unrelated to the  
186 allergen exposure and the allergen-specific IgE reactivity, minimizing the risk for selection bias  
187 (Fig. S1 and S2).

188

## 189 ***Statistical methods***

190 Demographic results are given in means  $\pm$  SD or n (%). For the analysis of the number of  
191 positive allergen-specific IgE, results are given in medians and 25-75 percentiles (Q1 and Q3).  
192 The level of allergen-specific IgE for each positive allergen molecule were compared between  
193 phenotypes using the non-parametric Kruskal Wallis test. Negative binomial regression model  
194 was applied to estimate age and sex adjusted associations with the number of positive  
195 allergen-specific IgE. This regression models the ratio of the mean number of positive allergen-  
196 specific IgE (and its 95% confidence interval) between the asthma and rhinitis phenotypes. For  
197 example, a ratio of 5.0 for asthma means that those with asthma had a 5-fold higher mean  
198 number of positive allergen-specific IgE, as compared with those without asthma. Logistic  
199 regression models were used to estimate Odds Ratio (OR) and their 95% CI associated with  
200 positive allergen-specific IgE.

201

## 202 **Results**

### 203 *Demographic characteristics of participants*

204 There were 840 adult participants to the French EGEA study (463 with and 377 without  
205 asthma) and 786 adolescents of the Swedish BAMSE cohort (Fig. S1 and S2). In BAMSE and  
206 within the asthma and the non-asthma group in EGEA, participants included in the analysis  
207 did not differ to those non-included regarding allergy related characteristics (Tables S4 and  
208 S5). In the BAMSE study, included participants had more often asthma than non-included ones  
209 (22.9% vs. 18.0%,  $p=0.02$ ). The demographic characteristics of the participants are presented  
210 in Table 1. In EGEA, mean age of asthma onset was higher in the A+R- than in the A+R+ (19.4  
211 ( $\pm 16.0$ ) vs. 13.7 ( $\pm 14.6$ ),  $p=0.002$ ). The frequency of asthma-rhinitis multimorbidity (A+R+)

212 was 44% in EGEA and 14% in BAMSE. Asthma only (A+R-) and rhinitis only (A-R+) were found  
213 in 11% and 15% in EGEA and 8% and 24% in BAMSE.

214

### 215 ***IgE reactivity to allergen molecules***

216 We identified 39 and 18 allergens recognized by IgE in at least 3% of the EGEA population and  
217 the BAMSE population, respectively (Table S1). IgE-reactivities to olive Ole e 1 and house dust  
218 mite Der p 1 were frequent in EGEA (20.4% and 26.4% respectively) and infrequent in BAMSE  
219 (1.2% and 1.3%). IgE-reactivity to birch Bet v 1 was frequent in BAMSE. IgE-reactivities to  
220 animal (cat, dog and horse) and grass pollen allergens were similar in both populations  
221 irrespective of age difference between the two studies.

222

### 223 ***Multimorbidity and polysensitization***

224 The number of subjects with IgE reactivity to at least one allergen and the number of IgE-  
225 reactive allergens differed significantly between the asthma-rhinitis phenotypes in both  
226 studies. IgE sensitizations to few allergens were observed in the A-R- phenotype whereas the  
227 greatest number of IgE-reactive allergens was found in the multimorbid A+R+ phenotype  
228 (Table 2, Fig. 1-A). The A+R- and A-R+ phenotypes showed IgE reactivity to significantly fewer  
229 allergens than the A+R+ phenotype ( $p < 0.001$ ). As compared to A-R- subjects, the age and sex  
230 adjusted ratio of the mean number of IgE sensitizations was significantly higher in A+R+ than  
231 in A+R- or A-R+, in both cohorts (Table 2). There was a difference between EGEA and BAMSE  
232 since the A+R- group showed IgE reactivity to significantly more allergens in EGEA than in  
233 BAMSE.

234 In EGEA, the number of allergen molecules associated with specific IgE was significantly higher  
235 in childhood-onset asthma than in adult-onset asthma (median were 9.0 and 2.0, respectively,  
236  $p < 0.0001$ ) (Fig. 1B and Table 2). In both childhood and adult-onset asthma, the A+R+  
237 phenotype exhibited IgE reactivity to a higher number of allergens than the A+R- ( $p < 0.001$  in  
238 childhood-onset asthma and  $p = 0.002$  in adult-onset asthma) (Table 2). Among subjects with  
239 rhinitis, the number of allergen recognized by IgE was higher among subjects with childhood-  
240 onset asthma as compared to adult-onset asthma ( $p < 0.0001$ ).

241 In both studies, the prevalence of subjects with IgE reactivity to at least one allergen and the  
242 number of IgE-reactive allergens increased gradually with the number of diseases (asthma and  
243 rhinitis and atopic dermatitis) (Table 3). For each additional allergic disease phenotype, the  
244 number of IgE-reactive allergens increased significantly. However, among subjects with  
245 asthma and rhinitis, atopic dermatitis was not associated with the number of IgE-reactive  
246 allergens (age and sex adjusted relative change [95% CI] = 1.1 [0.9-1.3],  $p = 0.29$  in EGEA and  
247 1.2 [0.8-1.7],  $p = 0.41$  in BAMSE). The median level of allergen-specific IgE among positive  
248 allergen molecule increased with the number of diseases ( $p < 0.0001$  in EGEA and BAMSE, Table  
249 3), although in EGEA the trend was not linear, with a median level of similar magnitude in  
250 participants with 2 and 3 diseases.

251

### 252 ***Sensitization patterns between asthma and rhinitis phenotypes***

253 The patterns of IgE sensitizations differed between the phenotypes and populations (Fig. 2  
254 and 3). In the A-R- phenotype, IgE-reactivity frequency was below 10% for all allergen  
255 components in both cohorts, except for Phl p 1 in BAMSE (Fig. 2-A, 3-A). In the A+R-  
256 phenotype, Phl p 1, most of the Der p allergens and Fel d 1 were over 10% in EGEA (Fig. 2-B),

257 whereas only Phl p 1 was over the threshold of 10% in BAMSE (Fig. 3-B). In the A-R+  
258 phenotype, pollen allergens and Fel d 1 were over 10% in both EGEA and BAMSE (Fig. 2-C and  
259 3-C). In BAMSE Can f 5 was also over the threshold of 10% recognition in the A-R+ phenotype.  
260 In the A+R+ phenotype (Fig. 2-D and 3-D), 24 allergen molecules in EGEA (61.5% of the 39  
261 allergens recognised by at least 3% of the EGEA population) and 17 allergens in BAMSE (94.4%  
262 of the 18 allergens recognised by at least 3% of the BAMSE population) were over the 10% IgE  
263 recognition frequency. Although the A+R- and A-R+ sensitization patterns differed between  
264 the EGEA and BAMSE populations, in both studies the A+R+ sensitization pattern results from  
265 the combination of the A+R- and A-R+ sensitization patterns.

266 For the three allergens with the highest IgE-reactivity frequency in the A-R- (Phl p 1, Ole e 1,  
267 and Der p 23 in EGEA with IgE-reactivity frequency in A-R- of 9.5%, 6.0% and 7.0%; Phl p 1, Bet  
268 v 1 and Fel d 1 in BAMSE with IgE-reactivity frequency in A-R- of 15.6%, 7.6% and 5.9%,  
269 respectively) we estimated the risk for A-R+, A+R- and A+R+ as compared to A-R- (Fig. 4). In  
270 both studies and for each allergen component, the OR was always the highest for A+R+,  
271 although the risk in A+R+ did not statistically differ from the risk in A-R+ or A+R-. In EGEA, the  
272 OR point estimate for A+R+ was approximately the addition of the OR point estimate for A+R-  
273 and A-R+. In BAMSE, none of these three allergen molecules was associated with the asthma  
274 only phenotype (OR point estimates were close to 1).

275

## 276 Discussion

277 Our study shows that the asthma-rhinitis multimorbid phenotype is associated with strong  
278 IgE-polysensitisation, both in adolescents and in adults. The asthma-rhinitis multimorbid

279 phenotype combined the sensitization pattern of both the asthma-only phenotype and the  
280 rhinitis-only phenotype. In addition, the systematic highest risk observed for allergen specific-  
281 IgE reactivity in the asthma-rhinitis multimorbid phenotype as compared to the asthma- or  
282 rhinitis-only phenotypes, indicates that the mechanisms involved in the asthma-rhinitis  
283 multimorbid phenotype might be partly different or enhanced than those involved in asthma-  
284 or rhinitis-only phenotypes. The observation found in two different populations with exposure  
285 to different allergen sources, the Swedish BAMSE cohort and the French EGEA population,  
286 provides evidence for the generalizability of this “extreme” phenotype to any age or allergenic  
287 environment.

288 A major strength of our study is the strategy used, by addressing the research question in two  
289 populations differing regarding many features including population age (including adolescents  
290 and adults), study design (birth cohort and case-control combined to a family study) and  
291 allergen exposure due to different environments (Sweden with a high birch pollen exposure  
292 and France with a high mite exposure). Long-term birth cohort studies are essential to  
293 understand disease mechanisms and life course of allergic diseases,(30) but in population-  
294 based studies individuals with severe disease are rare. Therefore, patient cohorts can be  
295 combined with population-based studies to fill gaps of unmet needs of birth cohorts (30) for  
296 a better definition of disease phenotypes and stratification. Similar observations in the two  
297 populations provide evidence that the observed associations are not due to uncontrolled bias  
298 affecting a single study or by chance. A further asset relies in the precise characterisation of  
299 the allergic sensitization, by assessing IgE sensitization to well-defined allergen molecules  
300 which allow to discriminate co- and cross-sensitization. The MeDALL micro-array has been  
301 established and was carefully validated regarding specificity and sensitivity in the FP7-funded  
302 EU program MeDALL and has previously been successfully used in several studies including

303 the EGEA and BAMSE cohorts.(7, 22, 28)

304 One limitation, relying on the cross-sectional design of our analyses, is the lack of definite  
305 information on the timing of the events and of the successive specific allergens sensitization.  
306 This timing of events has been addressed in some birth cohort studies. However, none of these  
307 previous studies has used defined allergen molecules but only allergen extracts to detect IgE  
308 sensitization. A recent study in the MAS and PASTURE cohorts, which identified different  
309 sensitisation profiles characterized by allergen specificity, time course and sIgE level, did not  
310 identify clear temporal sensitization pattern between 1 and 6 years of age.(31) The clusters  
311 were mainly characterized by allergen specificity and strength of the sIgE sensitization. In the  
312 Paris cohort, Gabet et al identified as early as 18 months of age three sensitization profiles,  
313 including a “polysensitized” profile which exhibits the highest risk for multimorbidity at 6  
314 years.(8) In the EGEA study, we examined the impact of age of asthma onset on the  
315 sensitization patterns. When the disease started in childhood, the number of sensitizations  
316 was greater than when the disease started later for both A+R- and A+R+ groups. But, the  
317 association between the asthma-rhinitis multimorbidity and allergic polysensitization was  
318 observed in both childhood- and adult-onset phenotypes. Another limitation could be that  
319 IgE measurements on the chip are performed under conditions of low amounts of allergen  
320 immobilized to the solid phase which may be affected by allergen-specific IgG antibodies.  
321 However, the MeDALL allergen-chip has been carefully evaluated with respect to sensitivity  
322 and was found to be more sensitive for detecting IgE sensitization than allergen-extract-based  
323 skin prick testing and conventional allergen extract-based serology because significantly more  
324 sensitized subjects were detected.(22)

325 Our study is clinically relevant and provides results with a general validity because it examines  
326 asthma-rhinitis multimorbidity and polysensitization in depth and confirms the hypothesis  
327 raised in the recent paper by Burte et al in the same EGEA cohort using classical IgE tests for  
328 12 aeroallergens sources.(16) It is novel as it uses the most advanced method of IgE  
329 measurement that is needed to accurately assess true polysensitization, allowing for the  
330 assessment of IgE-reactivity to define allergen molecules. Moreover, similar findings were  
331 observed in a second cohort which allow the generalizability of the results. For the first time,  
332 our study showed that for specific allergens with high IgE recognition frequency in the study  
333 populations, the risk of IgE-reactivity was the highest in the asthma-rhinitis multimorbid  
334 phenotype as compared to the isolated asthma or rhinitis phenotypes. This might suggest that  
335 the biological mechanisms involved in the association between IgE-sensitization and the AR  
336 phenotypes are partly different or enhanced in the AR multimorbidity phenotype. Moreover,  
337 in the EGEA study we observed that the magnitude of the risk for the AR multimorbidity  
338 phenotype was roughly the addition of the risk observed in asthma alone and rhinitis alone  
339 phenotypes. This might suggest independent effects of allergen-specific IgE-sensitisation in  
340 asthma and in rhinitis (if the effects were mainly shared, the risk in A+R+ would not be higher  
341 than the risk in A+R- or A-R+). Our observations provide hypotheses for novel biological  
342 explanations which warrants further investigations.

343 The major difference across the two study populations is related to the allergen exposure. In  
344 Sweden, exposure to mites is very low, and low level of IgE-reactivity to mite allergens  
345 probably explains differences in the total number of allergen recognized between EGEA and  
346 BAMSE and the lack of sensitization in A+R- patients in Sweden. Moreover, in Sweden birch  
347 pollen is highly prevalent whereas it is not common in most parts of France.(7, 28) Thus, the  
348 prevalence of birch-related IgE is higher in Sweden than in France. Finally, Ole e 1 is the major

349 allergen of olive and it displays strong cross-reactivity with Fra e 1, a major ash allergen.(32,  
350 33) These two species are common in France but not in Sweden, which explain the low  
351 prevalence of Ole e 1-specific IgE in BAMSE as compared to EGEA.

352 If we consider the impact of environmental exposure, the results are similar in both studies  
353 and show that allergic multimorbidity is associated with IgE-polysensitization in adults  
354 (France) and adolescents (Sweden). Moreover, the levels of allergen-specific IgE are  
355 associated with the number of co-existing allergic disease phenotypes. Our study extends to  
356 adolescents and adults recent findings in childhood studies and therefore indicates that the  
357 allergy multimorbid IgE-polysensitized phenotype starts early in life and does not remit over  
358 time, but seems to remain persistent across the life course. In addition, we observed that AR  
359 multimorbidity is associated with IgE sensitization to significantly more allergen molecules as  
360 compared with asthma alone both in childhood- and adult-onset asthma, emphasizing the  
361 generalizability of this phenotype. Recent studies in children showed that this phenotype is  
362 associated with the severity of asthma and rhinitis,(11-13, 15) and therefore underline the  
363 relevance of this phenotype at the clinical and public health level. By investigating pathways  
364 related to asthma severity in children with asthma and rhinitis, Liu et al. showed that allergy  
365 was associated with asthma severity through several pathways, from allergic inflammation  
366 and subsequently through pulmonary physiology or rhinitis severity.(12)

367 Our study clearly demonstrated different patterns of sensitization according to the asthma  
368 and rhinitis phenotypes, with no or few sensitizations in the A-R- group, with no or  
369 predominant sensitization to indoor allergens in A+R-, predominant pollen allergens in A-R+,  
370 and frequent IgE-sensitization to both pollen and indoor allergens in A+R+. Differences in the  
371 A+R- sensitization patterns between EGEA and BAMSE might partly be explained by

372 differences in allergenic environment, in particular the infrequent sensitization to house dust  
373 mite allergens in Sweden, and differences in the asthma phenotypes considered (e.g. EGEA  
374 also includes adult-onset asthma, which might have different IgE-sensitization pattern).

375 In conclusion, our study provides new insights into the patterns of allergic sensitization across  
376 the AR phenotypes in both adolescents and adults. By showing that the allergy multimorbid  
377 polysensitized phenotype, previously identified in early life, seems to remain persistent across  
378 the life-course, our findings advocate for paying a particular attention to this specific  
379 phenotype, to identify its underlying mechanisms and risk factors.

380

## 381 **Acknowledgments**

382 The authors thank all those who participated to the setting of the EGEA and BAMSE studies  
383 and on the examinations of the individuals. The authors are grateful to the three CIC-Inserm  
384 of Necker, Grenoble and Marseille who supported the EGEA study and in which participants  
385 were examined. They are indebted to all the individuals who participated to the EGEA study  
386 without whom the study would not have been possible. In addition, the authors thank the  
387 children and parents participating in the BAMSE cohort.

388 We thank the Epidemiological Study on Genetics and Environment of Asthma (EGEA)  
389 cooperative group members as follows. **Coordination:** V Siroux (epidemiology, PI since 2013);  
390 F Demenais (genetics); I Pin (clinical aspects); R Nadif (biology); F Kauffmann (PI 1992-2012).  
391 **Respiratory epidemiology:** Inserm ex-U 700, Paris: M Korobaeff (Egea1), F Neukirch (Egea1);  
392 Inserm ex-U 707, Paris: I Annesi-Maesano (Egea1-2); Inserm ex-U 1018, Villejuif: F Kauffmann,  
393 MP Oryszczyn (Egea1-2); Inserm U 1168, Villejuif: N Le Moual, R Nadif, R Varraso; Inserm U  
394 1209 Grenoble: V Siroux. **Genetics:** Inserm ex-U 393, Paris: J Feingold; Inserm U 946, Paris: E  
395 Bouzigon, F Demenais, MH Dizier; CNG, Evry: I Gut (now CNAG, Barcelona, Spain), M Lathrop  
396 (now Univ McGill, Montreal, Canada). **Clinical centers:** Grenoble: I Pin, C Pison; Lyon: D  
397 Ecochard (Egea1), F Gormand, Y Pacheco; Marseille: D Charpin (Egea1), D Vervloet (Egea1-2);  
398 Montpellier: J Bousquet; Paris Cochin: A Lockhart (Egea1), R Matran (now in Lille); Paris  
399 Necker: E Paty (Egea1-2), P Scheinmann (Egea1-2); Paris-Trousseau: A Grimfeld (Egea1-2), J  
400 Just. **Data and quality management:** Inserm ex-U155 (Egea1): J Hochez; Inserm U 1168,  
401 Villejuif: N Le Moual; Inserm ex-U780: C Ravault (Egea1-2); Inserm ex-U794: N Chateigner  
402 (Egea1-2); Grenoble: J Quentin (Egea1-2).

403

404

405 **Conflict of interests statements**

406 Rudolf Valenta has received research grants from Biomay AG, Vienna, Austria and Virvaxx,  
407 Vienna, Austria. He serves as a consultant for Biomay AG, Vienna, Austria, Viravaxx, Vienna,  
408 Austria and Fresenius Medical Care, Bad Homburg, Germany. Valerie Siroux has received  
409 speaker honorarium from TEVA, AstraZeneca and Novartis-France, outside the submitted  
410 work. Jean Bousquet serves in scientific advisory boards from Almirall, Meda, Merck, MSD,  
411 Novartis, Sanofi-Aventis, Takeda, Teva, Uriach. Magnus Wickman has received research  
412 grants from ThermoFisher Scientific. Jocelyne Just serves in scientific advisory boards from -  
413 ALK, Stallergenes Greer, Thermofisher, AstraZeneca and Novartis-France, outside the  
414 submitted work.

415

416 **Authors contributions**

417 V Siroux, C Lupinek, I Pin, J Just, R Nadif, JM Anto, E Melen, R Valenta, M Wickman and J  
418 Bousquet contributed to the data acquisition. V Siroux, N Balardini, M Soler and A Boudier  
419 conducted the statistical analyses. V Siroux and J Bousquet drafted the first version of the  
420 manuscript. All authors contributed to the interpretation of the data, critically revised the  
421 manuscript and approved the final version.

422

423 **Sources of funding:** The study was supported in part by Inserm Aviesan Itmo santé publique,  
424 the Scientific committee “AGIR for chronic diseases”, ANR-PRSP 2009, grant F4605 of the  
425 Austrian Science Fund (FWF) to RV and by the European Commission’s Seventh Framework  
426 Program MeDALL under grant agreement no. 261357. In addition, the BAMSE study was

427 supported by grants from the Swedish Heart-Lung Foundation, the Swedish Research Council  
428 and Stockholm County Council.

## References

1. Zellweger F, Eggel A. IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment. *Allergy* 2016;**71**:1652-1661.
2. Pinart M, Benet M, Annesi-Maesano I, von Berg A, Berdel D, Carlsen KC, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitized and non-IgE-sensitized children in MeDALL: a population-based cohort study. *Lancet Respir Med* 2014;**2**:131-140.
3. Custovic A, Sonntag HJ, Buchan IE, Belgrave D, Simpson A, Prospero MC. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. *J Allergy Clin Immunol* 2015;**136**:1645-1652 e1641-1648.
4. Bousquet J, Anto JM, Bachert C, Bousquet PJ, Colombo P, Cramer R, et al. Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GALEN project. *Allergy* 2006;**61**:671-680.
5. Bousquet J, Anto JM, Wickman M, Keil T, Valenta R, Haahtela T, et al. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis. *Allergy* 2015;**70**:1062-1078.
6. Westman M, Lupinek C, Bousquet J, Andersson N, Pahr S, Baar A, et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. *J Allergy Clin Immunol* 2015;**135**:1199-1206 e1191-1111.
7. Asarj A, Hamsten C, Waden K, Lupinek C, Andersson N, Kull I, et al. Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study. *J Allergy Clin Immunol* 2016;**137**:813-821 e817.
8. Gabet S, Just J, Couderc R, Bousquet J, Seta N, Momas I. Early polysensitization is associated with allergic multimorbidity in PARIS birth cohort infants. *Pediatr Allergy Immunol* 2016;**27**:831-837.
9. Ballardini N, Bergstrom A, Wahlgren CF, van Hage M, Hallner E, Kull I, et al. IgE antibodies in relation to prevalence and multimorbidity of eczema, asthma, and rhinitis from birth to adolescence. *Allergy* 2016;**71**:342-349.
10. Just J, Saint-Pierre P, Gouvis-Echraghi R, Laoudi Y, Roufai L, Momas I, et al. Childhood allergic asthma is not a single phenotype. *J Pediatr* 2014;**164**:815-820.

11. Zoratti EM, Krouse RZ, Babineau DC, Pongracic JA, O'Connor GT, Wood RA, et al. Asthma phenotypes in inner-city children. *J Allergy Clin Immunol* 2016;**138**:1016-1029.
12. Liu AH, Babineau DC, Krouse RZ, Zoratti EM, Pongracic JA, O'Connor GT, et al. Pathways through which asthma risk factors contribute to asthma severity in inner-city children. *J Allergy Clin Immunol* 2016;**138**:1042-1050.
13. Pongracic JA, Krouse RZ, Babineau DC, Zoratti EM, Cohen RT, Wood RA, et al. Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. *J Allergy Clin Immunol* 2016;**138**:1030-1041.
14. Amat F, Saint-Pierre P, Bourrat E, Nemni A, Couderc R, Boutmy-Deslandes E, et al. Early-onset atopic dermatitis in children: which are the phenotypes at risk of asthma? Results from the ORCA cohort. *PLoS One* 2015;**10**:e0131369.
15. Just J, Elegbede CF, Deschildre A, Bousquet J, Moneret-Vautrin DA, Crepet A, et al. Three peanut-allergic/sensitized phenotypes with gender difference. *Clin Exp Allergy* 2016;**46**:1596-1604.
16. Burte E, Bousquet J, Siroux V, Just J, Jacquemin B, Nadif R. The sensitization pattern differs according to rhinitis and asthma multimorbidity in adults: the EGEA study. *Clin Exp Allergy* 2017;**47**:520-529.
17. Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. *Int Arch Allergy Immunol* 2002;**127**:259-268.
18. Pfiffner P, Stadler BM, Rasi C, Scala E, Mari A. Cross-reactions vs co-sensitization evaluated by in silico motifs and in vitro IgE microarray testing. *Allergy* 2012;**67**:210-216.
19. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A, et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. *FASEB J* 2002;**16**:414-416.
20. Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE, et al. A WAO - ARIA - GA(2)LEN consensus document on molecular-based allergy diagnostics. *World Allergy Organ J* 2013;**6**:17.

21. Lupinek C, Wollmann E, Baar A, Banerjee S, Breiteneder H, Broecker BM, et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. *Methods* 2014;**66**:106-119.
22. Skrindo I, Lupinek C, Valenta R, Hovland V, Pahr S, Baar A, et al. The use of the MeDALL-chip to assess IgE sensitization: a new diagnostic tool for allergic disease? *Pediatr Allergy Immunol* 2015;**26**:239-246.
23. Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, et al. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. *Allergy* 2011;**66**:596-604.
24. Kauffmann F, Dizier MH, Annesi-Maesano I, Bousquet J, Charpin D, Demenais F, et al. EGEA (Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy)-- descriptive characteristics. *Clin Exp Allergy* 1999;**29 Suppl 4**:17-21.
25. Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a prospective longitudinal birth cohort study. *Pediatr Allergy Immunol* 2002;**13 Suppl 15**:11-13.
26. Kauffmann F, Dizier MH, Pin I, Paty E, Gormand F, Vervloet D, et al. Epidemiological study of the genetics and environment of asthma, bronchial hyperresponsiveness, and atopy: phenotype issues. *Am J Respir Crit Care Med* 1997;**156**:S123-129.
27. Bouzigon E, Corda E, Aschard H, Dizier MH, Boland A, Bousquet J, et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. *N Engl J Med* 2008;**359**:1985-1994.
28. Siroux V, Lupinek C, Resch Y, Curin M, Just J, Keil T, et al. Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study. *J Allergy Clin Immunol* 2017;**139**:643-654.
29. Wickman M, Lupinek C, Andersson N, Belgrave D, Asaranoj A, Benet M, et al. Detection of IgE Reactivity to a Handful of Allergen Molecules in Early Childhood Predicts Respiratory Allergy in Adolescence. *EBioMedicine* 2017.

30. Bousquet J, Gern JE, Martinez FD, Anto JM, Johnson CC, Holt PG, et al. Birth cohorts in asthma and allergic diseases: report of a NIAID/NHLBI/MeDALL joint workshop. *J Allergy Clin Immunol* 2014;**133**:1535-1546.
31. Hose AJ, Depner M, Illi S, Lau S, Keil T, Wahn U, et al. Latent class analysis reveals clinically relevant atopy phenotypes in 2 birth cohorts. *J Allergy Clin Immunol* 2017;**139**:1935-1945.
32. Imhof K, Probst E, Seifert B, Regenass S, Schmid-Grendelmeier P. Ash pollen allergy: reliable detection of sensitization on the basis of IgE to Ole e 1. *Allergo J Int* 2014;**23**:78-83.
33. Barderas R, Purohit A, Rodriguez R, Pauli G, Villalba M. Isolation of the main allergen Fra e 1 from ash (*Fraxinus excelsior*) pollen: comparison of the natural and recombinant forms. *Ann Allergy Asthma Immunol* 2006;**96**:557-563.

## Figures legend

**FIGURE 1.** Distribution of the number of IgE-reactive allergens ( $\geq 0.3$  ISU) according to the asthma and rhinitis phenotypes in EGEA and in BAMSE (A) and taking into account age of asthma onset in EGEA (B) (among the 64 allergen components).

In these box plots, the bottom and the top of the rectangle indicate the first and the third quartile, respectively, and the horizontal line near the middle of the rectangle indicates the median. The vertical lines from the top and the bottom of the rectangle indicate the maximum and minimum values, respectively. The diamond indicates the mean value.

**FIGURE 2.** IgE recognition frequencies and intensities to respiratory allergens recognized by  $>3\%$  of the EGEA samples according to the combined asthma and rhinitis phenotypes in EGEA with: (A) no asthma and no rhinitis (A-R-), (B) asthma but no rhinitis (A+R-), (C) no asthma but rhinitis (A-R+), and (D) asthma and rhinitis (A+R+)

**FIGURE 3.** IgE recognition frequencies and intensities of respiratory allergens recognized  $>3\%$  of the BAMSE samples according to the combined asthma and rhinitis phenotypes in BAMSE with: (A) no asthma and no rhinitis (A-R-), (B) asthma but no rhinitis (A+R-), (C) no asthma but rhinitis (A-R+), and (D) asthma and rhinitis (A+R+)

**FIGURE 4.** Age- and sex-adjusted association (OR (95% CI)) between the asthma-rhinitis phenotypes and the three allergen components with the highest IgE-reactivity frequency in the A-R- group. A) In EGEA, B) in BAMSE